Therapeutic options for management of endometrial hyperplasia
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Endometrial hyperplasia (EH) comprises a spectrum of changes in the endometrium ranging from a slightly disordered pattern that exaggerates the alterations seen in the late proliferative phase of the menstrual cycle to irregular, hyperchromatic lesions that are similar to endometrioid adenocarcinoma. Generally, EH is caused by continuous exposure of estrogen unopposed by progesterone, polycystic ovary syndrome, tamoxifen, or hormone replacement therapy. Since it can progress, or often occur coincidentally with endometrial carcinoma, EH is of clinical importance, and the reversion of hyperplasia to normal endometrium represents the key conservative treatment for prevention of the development of adenocarcinoma. Presently, cyclic progestin or hysterectomy constitutes the major treatment option for EH without or with atypia, respectively. However, clinical trials of hormonal therapies and definitive standard treatments remain to be established for the management of EH. Moreover, therapeutic options for EH patients who wish to preserve fertility are challenging and require nonsurgical management. Therefore, future studies should focus on evaluation of new treatment strategies and novel compounds that could simultaneously target pathways involved in the pathogenesis of estradiol-induced EH. Novel therapeutic agents precisely targeting the inhibition of estrogen receptor, growth factor receptors, and signal transduction pathways are likely to constitute an optimal approach for treatment of EH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endocrine regulation of menstruation
Jabbour, H. N., Kelly, R. W., Fraser, H. M., & Critchley, H. O. D. (2006) · Endocrine Reviews · doi:10.1210/er.2004-0021 · Cited by 588 · cited 1×
“The endometrium, the innermost glandular layer of the uterus, is a dynamic tissue that goes through a series of alterations (proliferation, secretion and menstruation/shedding) during the menstrual cycle in a woman’s reproductive years [1].”
BackgroundMetformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313 · cited 1×
“Metformin Metformin (N,N-dimethylbiguanide) belonging to a class biguanides is commonly used for the treatment of type 2 diabetes mellitus [125] and PCOS, especially in over-weight and obese individuals [126], or in cases when insulin resistance may be an important factor [127].”
BackgroundMolecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis
Shang, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1879 · Cited by 246
Advances in the management of endometriosis: an update for clinicians
Crosignani, P., Olive, D., Bergqvist, A., & Luciano, A. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi049 · Cited by 237
PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia
Hayes, M. P., Wang, H., Espinal-Witter, R., Douglas, W., Solomon, G. J., Baker, S. J., & Ellenson, L. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1375 · Cited by 218 · cited 1×
“The most common genetic alterations in endometrial lesions (atypical EH or endometrioid endometrial carcinomas) are microsatellite instability (MSI) [57], PTEN mutations [58], K-ras mutation [59], beta-catenin mutation [60] and PIK3CA mutation [61].”
BackgroundEndometriosis: Current Therapies and New Pharmacological Developments
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G. (2009) · Drugs · doi:10.2165/00003495-200969060-00002 · Cited by 182
Cited by
New concepts for an old problem: the diagnosis of endometrial hyperplasia
Sanderson, P. A., Critchley, H. O. D., Williams, A. R. W., Arends, M. J., & Saunders, P. T. K. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw042 · Cited by 323
Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143
“Cyclic progestin or hysterectomy constitutes the major treatment option for endometrial hyperplasia (364).”
BackgroundNeal, A. S., Nunez, M., Lai, T., Tosevska, A., Morselli, M., Amneus, M., Zakhour, M., Moatamed, N. A., Pellegrini, M., & Memarzadeh, S. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00175-w · Cited by 11
“Hormonal therapy using progesterone has been shown to be efficacious in the treatment of both conditions [4, 5].”
Metadata
- Authors
- Chandra, V., Kim, J. J., Benbrook, D. M., Dwivedi, A., & Rai, R.
- Venue
- Journal of Gynecologic Oncology
- Publisher
- XMLink
- Published
- 2016
- Volume
- 27
- Issue
- 1
- Pages
- e8-e8
- ISSN
- 2005-0380 (ISSN-L)
- 2005-0399
- OpenAlex
- W2185449028
- Cited by
- 223
- References
- 6
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic options for management of endometrial hyperplasia. https://app.cochat.ai/papers/10.3802/jgo.2016.27.e8
- The paper
- Chandra, V., Kim, J. J., Benbrook, D. M., Dwivedi, A., & Rai, R. (2016). Therapeutic options for management of endometrial hyperplasia. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2016.27.e8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.